T
Tomasz Hawro
Researcher at Charité
Publications - 66
Citations - 2405
Tomasz Hawro is an academic researcher from Charité. The author has contributed to research in topics: Omalizumab & Medicine. The author has an hindex of 24, co-authored 56 publications receiving 1662 citations. Previous affiliations of Tomasz Hawro include Medical University of Łódź & Humboldt University of Berlin.
Papers
More filters
Journal ArticleDOI
Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.
Karsten Weller,Adriane Groffik,Martin K. Church,Tomasz Hawro,Karoline Krause,Martin Metz,Peter Martus,Thomas B. Casale,Petra Staubach,Marcus Maurer +9 more
TL;DR: In this article, a 4-item UCT with a recall period of 4 weeks was developed based on 25 potential UCT items tested in 508 patients with chronic urticaria.
Journal ArticleDOI
Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials
Zuo-Tao Zhao,Chun-Mei Ji,Wen-Jun Yu,Ling Meng,Tomasz Hawro,Ji-Fu Wei,Marcus Maurer,Marcus Maurer +7 more
TL;DR: A meta-analysis of clinical trial results provided high-quality evidence for the efficacy and safety of omalizumab in patients with CSU and for treating these patients with 300 mg of o malizumAB every 4 weeks.
Journal ArticleDOI
Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria
Janine Gericke,Martin Metz,Tatevik Ohanyan,Karsten Weller,Sabine Altrichter,Per Stahl Skov,Sidsel Falkencrone,Janko Brand,Arno Kromminga,Tomasz Hawro,Martin K. Church,Marcus Maurer +11 more
Journal ArticleDOI
The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change
TL;DR: This study evaluated whether response rates to treatment with omalizumab in patients with CSU are linked to their baseline IgE levels, their IgE Levels after omalIZumab treatment, and the ratio of on treatment IgE and baseline Ig E levels.
Journal ArticleDOI
Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge.
TL;DR: The most intriguing function attributed to interleukin‐31 (IL‐31) is its ability to induce pruritus in pathologic conditions, such as atopic dermatitis (AD).